Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases

Journal of Clinical Oncology

Volumn 19, Issue 11, 2001, Pages 2804-2811

  Krance, R A ^a   Hurwitz, C A ^a   Head, D R ^a   Raimondi, S C ^a   Behm, F G ^a   Crews, K R ^a   Srivastava, D K ^a   Mahmoud, H ^a   Roberts, W M ^a   Tong, X ^a   Blakley, R L ^a   Ribeiro, R C ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROADENOSINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; NUCLEOSIDE ANALOG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

EID: 0035366389     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.11.2804     Document Type: Article

References (35)

1. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial - MRC Childhood Leukaemia Working Party
2. Improved treatment outcome results after risk-adapted intensification of chemotherapy in children with AML: Results of study AML-BFM 93
3. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
4. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia
5. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia
6. 2-chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia
7. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia
8. A program package for simulation and parameter estimation in pharmacokinetic systems
9. Nonparametric estimation from incomplete observations
10. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples
11. A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia
12. Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia
13. Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia
14. Definition of a standard-risk group in children with AML
15. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group
16. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood: Pediatric Oncology Group
17. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia: Results of the Medical Research Council's 10th AML trial (MRC AML10) - Adult and Childhood Leukaemia Working Parties of the Medical Research Council
18. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891
19. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial
20. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group
21. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: A report from the Children's Cancer Group
22. Factors associated with hematologic response to 2-chloro-deoxyadenosine in de novo pediatric acute myeloid leukemia
23. Circumvention of cytarabine resistance by 2-chloro-deoxyadenosine in pediatric acute myeloid and acute lymphoblastic leukemia: An in vitro study
24. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line
25. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML Study 8498
26. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia
27. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults
28. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia
29. Relationship between cladribine (CdA) plasma, intracellular CdA-5′-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL)
30. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions
31. Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia
32. Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′-deoxyadenosine
33. Additive action of gemcitabine (2′,2′-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388